Drugs that contain Quizartinib Dihydrochloride

1. Vanflyta patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8883783 DAIICHI SANKYO INC Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
Mar, 2027

(2 years from now)

US7820657 DAIICHI SANKYO INC Imidazolothiazole compounds for the treatment of disease
Sep, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585892 DAIICHI SANKYO INC Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
Mar, 2027

(2 years from now)

US8557810 DAIICHI SANKYO INC Imidazolothiazole compounds for the treatment of disease
Mar, 2027

(2 years from now)

US8129374 DAIICHI SANKYO INC Method of using imidazolothiazole compounds for the treatment of disease
Mar, 2027

(2 years from now)

US8865710 DAIICHI SANKYO INC Methods of treating proliferative diseases
Aug, 2029

(5 years from now)

US7968543 DAIICHI SANKYO INC Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
Aug, 2029

(5 years from now)

US8836218 DAIICHI SANKYO INC Methods of treatment using combination therapy
Mar, 2030

(5 years from now)

US9555040 DAIICHI SANKYO INC Methods of treating proliferative diseases
May, 2030

(5 years from now)

US8357690 DAIICHI SANKYO INC Methods of treatment using combination therapy
Feb, 2031

(6 years from now)

US9675549 DAIICHI SANKYO INC Tablet containing composite with cyclodextrin
Sep, 2033

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 20, 2028
Orphan Drug Exclusivity(ODE-437) Jul 20, 2030

NCE-1 date: 21 July, 2027

Market Authorisation Date: 20 July, 2023

Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...

Dosage: TABLET

More Information on Dosage

VANFLYTA family patents

Family Patents